CAR T and Other Emerging Therapies in R/R Multiple Myeloma: Kenneth H. Shain, MD, PhD

Video

The hematologist/oncologist at Moffitt Cancer Center discussed emerging therapies for patients with relapsed/refractory multiple myeloma.

This content originally appeared on our sister site, OncLive.

Recent Videos
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Related Content
enGene Snags FDA RMAT Designation for Bladder Cancer Gene Therapy Detalimogene

enGene Snags FDA RMAT Designation for Bladder Cancer Gene Therapy Detalimogene

Noah Stansfield
June 25th 2025
Article

The gene therapy is currently being evaluated in the phase 1/2 LEGEND clinical trial.

ImmunoLogic Episode 4

ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP

Joseph A. Fraietta, PhD;Janna Minehart, MD;Caroline Diorio, MD, FRCPC, FAAP;Noah Stansfield;Matt Hoffman
May 29th 2025
Podcast

In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.

Zhengzhou Revo-Gene Technology Assesses DC-CTL Cells for the Treatment of Solid Tumors in Real World Exploratory Study

Zhengzhou Revo-Gene Technology Assesses DC-CTL Cells for the Treatment of Solid Tumors in Real World Exploratory Study

Noah Stansfield
June 23rd 2025
Article

The study, which may enroll from 20 to 200 participants in total, will administer the DC-CTL cells 1 to 2 days after the patients have received conventional antitumor therapy.

ImmunoLogic

ImmunoLogic, Episode 3: "Breaking the Brain’s Barrier: CAR T-Cells Take on Glioblastoma" With Marcela Maus, MD, PhD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Marcela V. Maus, MD, PhD;Noah Stansfield;Matt Hoffman
April 8th 2025
Podcast

In Episode 3 of ImmunoLogic, Marcela Maus, MD, PhD, discussed her research on CAR-T for treating glioblastoma.

Top News and Expert Insights for World Sickle Cell Day 2025

Top News and Expert Insights for World Sickle Cell Day 2025

Noah Stansfield
June 19th 2025
Article

In honor of World Sickle Cell Day, observed annually on June 19, we took a look back at news and expert insights from the past year in cell and gene therapy for SCD.

Around the Helix: Cell and Gene Therapy Company Updates – June 18, 2025

Around the Helix: Cell and Gene Therapy Company Updates – June 18, 2025

Noah Stansfield
June 18th 2025
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

© 2025 MJH Life Sciences

All rights reserved.